Old versus new: weighing the evidence between the firstand second-generation antipsychotics

被引:22
|
作者
Davis, JM [1 ]
Chen, N [1 ]
机构
[1] Univ Illinois, Univ Maryland Psychiat Res Ctr, Dept Psychiat, Chicago, IL 60680 USA
关键词
antipsychotics; meta-analysis; efficacy; dose;
D O I
10.1016/j.eurpsy.2004.11.002
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
In our opinion the best guide to prescribing antipsychotics is the clinician's experience with his patients and in particular the patient being treated. If treatment works. stick with it. We feel it is also important for the clinician to consider the evidence front well-controlled double-blind random-assignment studies because in "evidence-based medicine," biases both known and unknown are controlled by blinding, and randomization. The purpose of this paper is to summarize and discuss the evidence on efficacy. Choice of antipsychotic. in our opinion. is probably the most important decision that the clinician makes for the psychotic patient. This involves the choice of drug. its dose. balancing efficacy, side-effects and cost. (C) 2004 Published by Elsevier SAS.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 50 条
  • [21] Second-generation antipsychotics and metabolic syndrome: a role for mitochondria
    Mortimer, Katherine R. H.
    Katshu, Mohammed Zia Ul Haq
    Chakrabarti, Lisa
    FRONTIERS IN PSYCHIATRY, 2023, 14
  • [22] Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth
    Pringsheim, Tamara
    Panagiotopoulos, Constadina
    Davidson, Jana
    Ho, Josephine
    PAEDIATRICS & CHILD HEALTH, 2012, 17 : 12B - 21B
  • [23] Metabolic Monitoring of Patients Prescribed Second-Generation Antipsychotics
    Dhamane, Amol D.
    Martin, Bradley C.
    Brixner, Diana I.
    Hudson, Teresa J.
    Said, Qayyim
    JOURNAL OF PSYCHIATRIC PRACTICE, 2013, 19 (05) : 360 - 374
  • [24] Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
    Caruso, Giuseppe
    Grasso, Margherita
    Fidilio, Annamaria
    Tascedda, Fabio
    Drago, Filippo
    Caraci, Filippo
    PHARMACEUTICALS, 2020, 13 (12) : 1 - 20
  • [25] Second-generation antipsychotics: are their similarities greater than their differences?
    Fleischhacker, WW
    EUROPEAN PSYCHIATRY, 2003, 18 : 38S - 45S
  • [26] Adjunctive second-generation antipsychotics for specific symptom domains of schizophrenia resistant to clozapine: A meta-analysis
    Bartoli, Francesco
    Crocamo, Cristina
    Di Brita, Carmen
    Esposito, Giovanni
    Tabacchi, Tommaso Innocenzo
    Verrengia, Enrica
    Clerici, Massimo
    Carra, Giuseppe
    JOURNAL OF PSYCHIATRIC RESEARCH, 2019, 108 : 24 - 33
  • [27] Obesity and coronary risk in patients treated with second-generation antipsychotics
    Correll, Christoph U.
    Kane, John M.
    Manu, Peter
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2011, 261 (06) : 417 - 423
  • [28] Obesity and coronary risk in patients treated with second-generation antipsychotics
    Christoph U. Correll
    John M. Kane
    Peter Manu
    European Archives of Psychiatry and Clinical Neuroscience, 2011, 261 : 417 - 423
  • [29] Changes in serum thyroid hormone levels in psychiatric patients treated with second-generation antipsychotics
    Zhang, Jia-Xuan
    Li, Xun
    ENDOKRYNOLOGIA POLSKA, 2020, 71 (04) : 292 - 298
  • [30] Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder
    Fugger, Gernot
    Bartova, Lucie
    Dold, Markus
    Fabbri, Chiara
    Fanelli, Giuseppe
    Zanardi, Raffaella
    Kautzky, Alexander
    Zohar, Joseph
    Souery, Daniel
    Mendlewicz, Julien
    Montgomery, Stuart
    Rujescu, Dan
    Serretti, Alessandro
    Kasper, Siegfried
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2022, 114